2011 Publications supported by the Fungal Infection Trust directly or indirectly

Adamama-Moraitou KK, Pardali D, Day MJ, Denning DW, Papazoglou L, Papastefanou A, Rallis TS. Aspergillus fumigatus Bronchopneumonia in a Hellenic Shepherd Dog. J Am Anim Hosp Assoc. 2011; 47: e13-8.

Albarrag AM, Anderson MJ, Howard SJ, Robson GD, Warn PA, Sanglard D, Denning DW. Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob Agents Chemother. 2011; 55: 5113-21.

Arendrup MC, Cuenca-Estrella M, Donnelly JP, Hope W, Lass-Flörl C, Rodriguez-Tudela JL; European committee on antimicrobial susceptibility testing – subcommittee on antifungal susceptibility testing (EUCAST-AFST). EUCAST technical note on posaconazole. Clin Microbiol Infect. 2011; 17: E16-7.

Arendrup MC, Rodriguez-Tudela JL, Lass-Flörl C, Cuenca-Estrella M, Donnelly JP, Hope W; European committee on antimicrobial susceptibility testing – subcommittee on antifungal susceptibility testing (EUCAST-AFST). EUCAST technical note on anidulafungin. Clin Microbiol Infect. 2011; 17:E18-20.

Baxter CG, Jones AM, Webb K, Denning DW Homogenisation of cystic fibrosis sputum by sonication–an essential step for Aspergillus PCR. J Microbiol Methods. 2011; 85: 75-81.

Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, Gore R, Smith J, Bueid A, Moore CB, Bowyer P, Perlin DS. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011; 52: 1123-9.

Fraczek MG, Bromley M, Bowyer P. An improved model of the Aspergillus fumigatus CYP51A protein. Antimicrob Agents Chemother. 2011 May;55(5):2483-6.

Gregson L, Hope WW, Howard SJ. In vitro model of invasive pulmonary aspergillosis in the human alveolus. Methods Mol Biol. 2012; 845: 361-7.

Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit. 2012;34: 72-6.

Howard SJ, Harrison E, Bowyer P, Varga J, Denning DW. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob Agents Chemother. 2011; 55: 4802-9.

Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis. 2011; 203: 1324-32.

Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother. 2011; 55: 4880-7.

Italia JL, Sharp A, Carter KC, Warn P, Kumar MN. Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™. PLoS One. 2011;6(10):e25744.

Lass-Flörl C, Arendrup MC, Rodriguez-Tudela JL, Cuenca-Estrella M, Donnelly P, Hope W; European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing. EUCAST technical note on Amphotericin B. Clin Microbiol Infect. 2011; 17: E27-9.

Purcell J, McKenna J, Critten P, Denning DW, Hassan IA. Mixed mould species in laboratory cultures of respiratory specimens: how should they be reported, and what are the indications for susceptibility testing? J Clin Pathol. 2011; 64: 543-5.

Segal BH, Cornely O, Bromley M. Proceedings from the 4th Advances Against Aspergillosis conference. Med Mycol. 2011 Apr;49 Suppl 1:S5-6.

Slater JL, Gregson L, Denning DW, Warn PA. Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice. Med Mycol. 2011;49 Suppl 1:S107-13.

Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother. 2011; 55: 3075-83.

Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wolkowiez M, Walsh TJ, Benjamin DK Jr, Hope WW. Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob Agents Chemother. 2012; 56:708-14.

Nagy GL, Petkovits T, Kovács GM, Vágvölgyi Cs, Papp T (2011) Where is the hidden fungal diversity hiding? In dusty herbaria or in the dust out there? New Phytologist, 191(3): 789-94.

Petkovits T, Nagy GL, Hoffmann K, Wagner L, Nyilasi I, Griebel T, Schnabelrauch D, Vogel, H, Voigt K, Vágvölgyi Cs, Papp T. (2011) Phylogeny of the zygomycetous family Mortierellaceae inferred from nuclear ribosomal DNA nucleotide sequences. Plos One, 6(11):e27507. doi:10.1371/journal.pone.0027507

Házi J, Nagy GL, Vágvölgyi Cs, Papp T. (2011) Coprinellus radicellus, a new species with northern distribution. Mycol Progress, 10(3) 363-371.

Nagy GL., Walther G., Vágvölgyi Cs., Papp T. (2011) Understanding the evolutionary processes of fungal fruiting bodies: correlated evolution and divergence times in the Psathyrellaceae. – Systematic Biology, 60(3):303–317.